Peptides interfering 3A protein dimerization decrease FMDV multiplication by González-Magaldi, Mónica et al.
RESEARCH ARTICLE
Peptides Interfering 3A Protein Dimerization
Decrease FMDV Multiplication
Mónica González-Magaldi1☯, Ángela Vázquez-Calvo1☯, Beatriz G. de la Torre2,
Javier Valle2, David Andreu2, Francisco Sobrino1*
1 Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Cantoblanco, Madrid, Spain, 2 Departament de
Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain
☯ These authors contributed equally to this work.
* fsobrino@cbm.csic.es
Abstract
Nonstructural protein 3A is involved in relevant functions in foot-and-mouth disease virus
(FMDV) replication. FMDV 3A can form homodimers and preservation of the two hydrophobic
α-helices (α1 and α2) that stabilize the dimer interface is essential for virus replication. In this
work, small peptides mimicking residues involved in the dimer interface were used to interfere
with dimerization and thus gain insight on its biological function. The dimer interface peptides
α1, α2 and that spanning the two hydrophobic α-helices, α12, impaired in vitro dimer forma-
tion of a peptide containing the two α-helices, this effect being higher with peptide α12. To
assess the effect of dimer inhibition in cultured cells, the interfering peptides were N-terminally
fused to a heptaarginine (R7) sequence to favor their intracellular translocation. Thus, when
fused to R7, interference peptides (100 μM) were able to inhibit dimerization of transiently
expressed 3A, the higher inhibitions being found with peptides α1 and α12. The 3A dimeriza-
tion impairment exerted by the peptides correlated with significant, specific reductions in the
viral yield recovered from peptide-treated FMDV infected cells. In this case, α2 was the only
peptide producing significant reductions at concentrations lower than 100 μM. Thus, dimer
interface peptides constitute a tool to understand the structure-function relationship of this
viral protein and point to 3A dimerization as a potential antiviral target.
Introduction
Foot-and-mouth disease virus (FMDV) is the etiological agent of the livestock disease that
causes the most severe economic losses in endemic areas, and whose reintroduction poses a
threat for disease-free countries. The FMDV particle encloses a plus stranded RNA genome of
about 8500 nucleotides that contains an open reading frame coding for four structural and
nine non-structural mature proteins, flanked by non-coding regions at the 3´and 5´ ends.
Non-structural protein 3A plays important roles in virus replication, virulence and host
range [1–3]. This 153-amino acid protein has a conserved N-terminal and a variable C-termi-
nal region in which several deletions and substitutions have been described to affect viral path-
ogenesis and virulence [4–6]. A membrane topology of the complete 3A protein has been
proposed in which the hydrophobic domain spanning residues 59–76 interacts with cellular
membranes leaving the N- and the C-termini of the molecule towards the cytosol [7]. A
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molecular model of the N-terminal fragment, derived from the structure reported for poliovi-
rus (PV) 3A [8], predicted a hydrophobic interface composed of two α-helices spanning resi-
dues 25 to 44 as the main determinant for 3A dimerization. In FMDV, 3A homodimerization
was evidenced by an in situ protein fluorescent ligation assay (PLA) [9]. Replacements L38E
and L41E, involving negative charge acquisition at residues predicted to contribute to the
hydrophobic interface, reduced dimerization and led to production of infective viruses where
the mutated acidic (E) residues reverted to non-polar ones, indicating that preservation of the
hydrophobic interface is essential for virus replication. In that same study a peptide reproduc-
ing the N-terminal domain of 3A of FMDV (residues I1 to F52, isolate C-S8c1), was shown by
Western blotting and mass staining to migrate in both monomeric and dimeric forms, repro-
ducing the dimerization observed in transiently expressed 3A and in infected cells.
Based on these results, we have explored the potential of small dimer interface peptides
spanning this region to interfere with in vitro 3A dimerization. Since short peptides do not eas-
ily penetrate cells, the interfering peptides were fused to a cell penetrating peptide (CPP)
sequence to ensure cellular uptake and eventually an effect on 3A dimer formation and FMDV
multiplication.
CPPs are short-to-midsize peptides (5–40 residues), usually cationic, derived from natural
sources or synthetically designed, with the ability to pass through cell membranes [10–13] and
successfully deliver cargos such as proteins, nucleic acids, small molecule therapeutics and
quantum dots, both in vivo and in vitro [14]. Poly-arginine oligomers are among the best
known CPPs, with translocation pathways similar to those of the HIV-1 Tat peptide [15–17].
Accordingly, a heptaarginine (R7) CPP sequence was fused N-terminal to dimerization-inter-
fering peptide candidates to ensure their delivery to susceptible cells.
Materials and Methods
Peptide design and synthesis
The N-terminal domain (residues 1–52) of protein 3A was assembled by solid phase synthesis
at 0.05-mmol scale on Rink-amide ChemMatrix resin (Iris Biotech). After deprotection and
cleavage from the resin, the peptide was purified by preparative HPLC using a linear gradient
of acetonitrile into water (both +0.1% TFA). Fractions of adequate homogeneity and the
expected mass (LC-MS 2010EV, Shimadzu) were used for biological assays. The partial α1 (res-
idues 25–33), α2 (37–44) and α12 (25–44) sequences, their R7-elongated (see Table 1 for
details) derivatives, as well as the octa-arginine control, were synthesized by similar protocols
on Rink-amide MBHA resin (Iris Biotech). Fluorescent versions of the peptides were made by
coupling 5(6)-carboxyfluorescein to the N-terminus.
Cells, viruses and antibodies
The origin of BHK-21 cells and culture procedures has been described [18]. A viral stock from
type C FMDV C-S8c1 isolate [19] was produced by amplification in BHK-21 cells. A bovine
enterovirus (BEV) [20] isolate was used as control for virus specificity. Monoclonal antibodies
(Abs) against the FMDV 3A (2C2), VP1 (SD6) and rabbit polyclonal antibodies to 3A (479)
and β-tubulin were employed [7, 9, 21].
Infection and virus titration
Cells were infected with FMDV at the multiplicity of infection (moi) indicated. After 60 min
adsorption, the viral inoculum was removed, cell monolayers washed twice with DMEM and
Interference Peptides as Antiviral Strategy
PLOS ONE | DOI:10.1371/journal.pone.0141415 October 27, 2015 2 / 12
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
fresh medium containing 1% FBS was added; this time point was considered 0 h post-infection
(p.i). Virus titration in semisolid agar medium was as described [9].
Dimer interference assay and in situ protein ligation assay (PLA)
For in vitro interference, 16.5 μm of the N-terminal (1–51) domain was incubated with differ-
ent molar ratios of interfering peptides (α1, α2, α12) and R8 negative control, at room tempera-
ture for 30 min. Next, sample buffer was added, peptides were resolved by 12% SDS-PAGE and
their migration monitored by Coomasie blue staining and western blotting. For in vivo inter-
ference, BHK-21 cells were grown on glass cover slips and incubated with 100 μM of either α1,
α2 or α12 R7-fused peptides for 1 h at 37°C. 24 h later, cells were transfected with 1 μg of
pcDNA3A using Lipofectamine 2000 (Life Technologies, Alcobendas, Spain). At 24 h post–
transfection (pt) monolayers were fixed in 4% paraformaldehyde and permeabilized as
described [7]. Primary Ab 2C2 was prepared using the Probemaker kit (OLINK, Bioscience) to
generate plus and minus PLA probes. Then, cells were incubated with conjugated primary Abs
and the signal development (ligation, amplification and hybridization) was performed as rec-
ommended the manufacturer. Finally, samples were further incubated with primary polyclonal
Ab 346 and anti-rabbit IgG secondary Abs coupled to Alexa Fluor (AF) 647 (Life Technologies)
to detect 3A protein. Slides were mounted with a cover slip using a minimal volume of Duolink
II mounting medium with DAPI. Cells were observed with a Confocal LSM710 Vertical (Carl
Zeiss Iberia, Tres Cantos, Spain) microscope. As reported for dimerization detection by PLA
[22], fluorescence was quantified using the ImageJ software (analyze particles plug-in), n10.
For interference with virus, BHK-21 cells grown overnight were treated with different con-
centrations of R7-fused peptides (α1, α2, α12) and R8 for 1 h at 37°C. Fresh medium was added
and after 24 h cells were infected with the corresponding virus and frozen at 8 h pi. For virus
titration, infected cells were subjected to three freeze-thaw cycles, and the total (intracellular
Table 1. Synthetic peptides used in this studya.
Mass
Peptideb 3A residues Sequenceb monoisotopic found
N-terminal (1–52) ISIPSQKSVLYFLIEKGQHEAAIEFFEGMVHDSIKEELRPLIQQTSFVKRAF 6036.0074 6036.563
α1 (25–33) FFEGMVHDS 1066.4542 1067.283
α2 (37–44) ELRPLIQQ 994.5924 995.924
α12 (25–44) FFEGMVHDSIKEELRPLIQQ 2414.2417 2415.972
R7-α1 (25–33) RRRRRRRXFFEGMVHDS 2272.2461 2273.995
R7-α2 (37–44) RRRRRRRXELRPLIQQ 2200.3842 2201.502
R7-α12 (25–44) RRRRRRRXFFEGMVHDSIKEELRPLIQQ 3620.0335 3621.505
Flu-α1 (25–33) Flu-FFEGMVHDS 1424.5020 1425.542
Flu-α2 (37–44) Flu-ELRPLIQQ 1352.6401 1353.505
Flu-α12 (25–44) Flu-FFEGMVHDSIKEELRPLIQQ 2772.2894 2774.500
Flu- R7-α1 (25–33) Flu-RRRRRRRXFFEGMVHDS 2630.2938 2631.063
Flu- R7-α2 (37–44) Flu-RRRRRRRXELRPLIQQ 2558.4319 2559.887
Flu- R7-α12 (25–44) Flu-RRRRRRRXFFEGMVHDSIKEELRPLIQQ 3978.0812 3980.426
R8 control RRRRRRRR 1266.5304 1267.219
a All peptides are C-terminal carboxamides
b Flu = ﬂuoresceine carboxylic acid; X = 6-aminohexanoic acid (spacer)
doi:10.1371/journal.pone.0141415.t001
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and medium-released) virus yield was determined by plaque assay in BHK-21 cells as described
[18].
Western blot analysis
BHK-21 cells incubated with peptides and infected were collected and processed as in [7].
Briefly, equal volumes of each sample were loaded on a SDS-PAGE 12%, transferred onto a
nitrocellulose membrane and the proteins detected by incubation with the selected primary
antibody and the corresponding horseradish peroxidase-coupled secondary antibody that was
developed using a chemiluminescence kit (Perkin-Elmer).
Cell viability test
The effect of CPPs on cell viability was determined using the CellTiter-Glo Luminiscent Cell
Viability assay (Promega). BHK-21 cells were seeded in 6-well plates and incubated with
increasing (0–100 μM) CPP concentrations for 24 h, then assayed as recommended by the
manufacturer.
R7-fused peptide penetration
Cells were grown on glass cover slips overnight and treated with 10 μM fluorescein-labelled
peptides for 30 min. Subsequently cells were fixed in 4% paraformaldehyde for 15 min at room
temperature, blocked and permeabilized as described [7]. Samples were incubated with phalloi-
din–tetramethylrhodamine B isothiocyanate (TRITC; Sigma) for 1 h to stain actin filaments
for light microscopy and To-Pro-3 (Life Technologies) was used as a nuclear counterstain.
Finally, samples were mounted in prolong gold antifade (Life Technologies) and cells were
observed with a Microradiance confocal (Carl Zeiss) microscope.
Data analysis
To probe statistical significance of the data, one-way analysis of the variance was performed
with the SPSS 21.0 statistical package (IBM; Armonk, NY) for Windows. For multiple compari-
sons, Bonferroni's correction was applied. The data are presented as means ± the standard
deviations and statistically significant differences are indicated in the figures by an .
Results
Peptide design and synthesis
Structural prediction of the N-terminus of 3A posits two alpha helices that mediate protein
homodimerization. Replacements at L38E and L41E reduced the dimerization signal in a pro-
tein ligation assay and prevented detection of dimer species in transiently expressed 3A (Gon-
zalez-Magaldi et al., 2012). To explore this evidence further, we designed three peptides
spanning helices α1 (residues 25–33), α2 (37–44) or both α12 (25–44) with a view to interfere
with 3A dimerization (Fig 1). To ensure efficient intracellular delivery, each interfering
sequence was extended at the N-terminus with seven Arg (R7) residues conferring cell pene-
trating peptide (CPP) properties (R7- fused peptides) followed by a 6-aminohexanoic acid flexi-
ble spacer residue. Fluorescein-labeled versions of all peptides (with or without R7) were also
made (Table 1). All peptides were obtained with high (>95% HPLC) purity by Fmoc solid
phase synthesis methods. In addition, octa-arginine (R8) used as negative control and the entire
N-terminal domain (residues 1–53) used as a dimerization model in vitro, were produced.
Interference Peptides as Antiviral Strategy
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CPP-fused peptides penetrate cells
We first evaluated the effect of peptides on cell viability. None of the R7-fused peptides, in the
10–100 μM concentration range examined, had noticeable effects on BHK-21 cell viability after
24 h treatment (Fig 2A). To evaluate the penetrating activity of R7-peptides we examined the
cellular uptake of their fluorescein (Flu)-labeled versions by confocal microscopy. Flu-labeled
α1, α2 and α12 lacking the R7 motifs were used as controls. Phaloidin was used to visualize the
cortical actin in order to make sure the green peptide fluorescent dots were inside the cell. Data
showed (Fig 2B) that R7-fused peptides were readily internalized into BHK-21 cells while pep-
tides devoid of the CPP moiety were not.
Peptides enhance 3A dimer dissociation
Different in vitro assays were designed to assess the effect of peptides on 3A dimerization. Syn-
thetic N-terminal (1–52) peptide was first used as a dimerization model, as described [9]. After
incubating with the interfering peptides lacking R7 (α1, α2 or α12), we analyzed dimerization
by coomasie blue staining (Fig 3A). In this assay, peptides α1 and α2 showed a rapid migration
and were not observed in the gels. On the other hand, the increase in the monomer band
observed for lower N-ter: α12 ratios reflected the accumulation of N-ter and α12 peptides
whose electrophoretic migration was similar. No clear differences were found in the intensity
of the dimer band observed when N-ter peptide was incubated with the interfering peptides,
relative to the N-ter peptide alone (Fig 3A). When dimerization was analyzed by immunoblot-
ting with polyclonal antibody 479, the only antibody available that recognized peptide N-ter, a
decrease in the intensity of the dimer band, relative to that of N-ter alone, was observed with
the three interfering peptides, being the effect higher for α12 (Fig 3A). In this case, detection of
the expected increase in the monomer band was impaired by the higher amount of monomer
as well as by the fact that antibody 479 mainly recognized the dimer, as reported [9].
Next, the ability of R7-fused peptides α1, α2 or α12 to interfere with dimerization of tran-
siently expressed 3A in BHK-21 cells was assayed. For that purpose, cells were incubated with
the peptides, and 24 h later were transfected with pcDNA3A. To assess 3A dimerization, in situ
PLA with a 3A-specific monoclonal Ab (2C2) was used (Fig 3B). The number of fluorescent
dots in transfected cells (expressing 3A protein) incubated with no peptide was taken as 100%
dimerization, and those in peptide-incubated cells were related to that value (Fig 3B). A
decreasing trend in 3A dimerization was observed for R7-fused peptides α1 and α12. The lack
of effect of peptide α2 in the dimerization of N-ter peptide (Fig 3A) could be due, among other
factors, to differences in the accessibility of α2 region in the in situ 3A PLA relative to the cell
free peptide dimerization assay.
Fig 1. Amino acid sequence (residues 1–153) of FMDV protein 3A. The two α-helices are represented in green and the hydrophobic region (HR) of the
protein in blue. Peptides used in this work are shown: N-ter (I1-F52) and three interfering peptides: α1(F25-S33), α2(E37-Q44) and α12(F25-Q44).
doi:10.1371/journal.pone.0141415.g001
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R7-fused peptides inhibit FMDV production
FMDV-susceptible BHK-21 cells were treated with increasing concentrations of R7- fused pep-
tides 24 h prior to FMDV infection (moi 1) and total viral production was titrated in BHK-21
Fig 2. CPP-fused peptides penetrate cells. (A) Effect of R7-elongated peptides on cell viability was determined by ATP measurement with CellTiter-Glo
1
luminescent cell viability assay. (B) BHK-21 cells were incubated with 10 μM of labeled peptides fused (Flu-R7-α1, Flu-R7-α2, Flu-R7-α12) or not (Flu-α1, Flu-
α2, Flu-α12) with R7 for 30 min at 37°C. Then, the samples were processed for confocal microscope analysis using phalloidin-TRITC (red) and To-Pro 3
(blue) to stain actin filaments and nuclei, respectively. Bar: 20 μm
doi:10.1371/journal.pone.0141415.g002
Interference Peptides as Antiviral Strategy
PLOS ONE | DOI:10.1371/journal.pone.0141415 October 27, 2015 6 / 12
cells. Relative to R8-treated control cells, the cells treated with R7-fused peptides α1, α2 and
α12 showed a dose dependent inhibition of viral production (Fig 4A). The highest inhibition
(ca. 50%) was found for peptide α2 at 100 μM.When the level of virus protein synthesis in
infected cells previously incubated with R7-fused peptides was quantified a decrease of VP1
protein was only observed for peptide α12 (Fig 4B). The reasons behind the differences in the
effect of the interfering peptides on the reduction of the viral titer and the synthesis of VP1 pro-
tein remain to be determined.
Fig 3. Peptides induce dimer dissociation. (A) A fixed concentration of 3A N-ter peptide was incubated with different ratios of interfering peptides lacking
R7 (α1, α2, α12) at room temperature for 30 min. The samples were resolved on two 12% SDS-PAGE parallel gels, one of which was stained with
Coomassie blue, the other transferred to nitrocellulose membrane and blotted with Ab 479. Bands intensities of dimer form of peptide N-ter were quantified
and expressed relative to that control of control sample (N-ter peptide alone). (B) BHK-21 cells were incubated with each R7-fused peptide (100 μM) and 24 h
later were transfected with pcDNA3A. Samples were next submitted to in situ PLA using a 3A-specific monoclonal Ab (2C2) coupled to two oligonucleotide
probes to assess 3A homodimerization. A negative control (mock) of non-transfected cells was included. Nuclei were stained using DAPI (blue). Graphs
represent percentage of dots relative to that of cells incubated with no peptide. Raw data were quantified using the ImageJ software (analyze particle plug in)
n10. Standard errors are represented.
doi:10.1371/journal.pone.0141415.g003
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When peptides were added at infection time, reductions, albeit of lower magnitude than
those observed at 24 h prior to infection were found, while no reductions were observed when
peptides were added 3 h p.i (Fig 4C). This result suggests that internalization of the interfering
peptides as to reach cell locations in which effectively interfere with virus replication is a time-
dependent process and that early steps of viral infection are more susceptible to peptide inter-
ference than latter infection stages.
Fig 4. R7-fused peptides inhibit FMDV production in BHK-21 cells. (A) Cells were incubated with different concentrations of R7-fused peptides (α1, α2
and α12) for 1h at 37°C; 24 h later cells were infected with C-S8c1 (moi of 1) and 8 h later the total viral titer was determined by plaque assay. Cells treated
with octaarginine (R8) were used as negative control. (B) Cells treated and infected as in (A). At 5 h p.i., cells were lysed and processed by western blot using
Ab SD6 to VP1 and 193 to β-tubulin. Quantitative densitometry of VP1 protein expression normalized for β-tubulin expression, and relative to that of
R8-treated infected cells, is indicated. (C) Cells were incubated for 1 h at 37°C with the different R7-fused peptides (100 μM) at the time of viral infection (t = 0)
or at 3 h p.i. (t = 3) with a moi of 1; 8 h later total viral titer was determined by plaque assay. (D) Cells were incubated with 100 μM of different R7-fused
peptides as before, 24 h later were infected with BEV (moi of 1) and 8 h pi the total viral titer was determined by plaque assay. Bars represent the mean
percentage of treated and infected cells ± SD, normalized to the level of infection of cells no peptide treated. Statistically significant differences between
untreated cells or peptide treated cells are indicated by an asterisk (ANOVA P0.05).
doi:10.1371/journal.pone.0141415.g004
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The specificity of the inhibition was confirmed by infecting peptide treated cells with bovine
enterovirus (BEV), a different picornavirus. Results in Fig 4D indicate that none of the peptides
exerted significant inhibitions on BEV growth.
Discussion
The formation of a protein dimer is a process that generally responds to a specific protein func-
tion or is a consequence of another protein interaction. There are many nonstructural proteins
of different picornaviruses [23–25], including FMDV [26] that are described to dimerize/multi-
merize. Recent structural and biophysical studies show that protein dimerization or oligomeri-
zation is a key factor in the regulation of different protein functions [27], including proteins
relevant for virus replication [28]. FMDV nonstructural protein 3A is involved in relevant
functions in virus replication [1, 29]. It shares common features with proteins from other
picornaviruses, albeit with structural and functional differences such as a longer amino acid
sequence and insensitivity to the Golgi disrupter brefeldin A [30, 31]. In common with poliovi-
rus and coxsackievirus, FMDV 3A can form homodimers whose biological function is not well
understood, although it could be related to the multimerization of other non-structural pro-
teins of different picornaviruses [26, 32].
Inhibition of viral proteins by molecules or small synthetic peptides is studying as antiviral
strategy few years ago [33, 34]. Moreover, small peptides mimicking residues involved in the
dimer interface have been used to interfere with dimerization and thus gain insight on its bio-
logical function [35]. Here, we intended to interfere with 3A dimerization and to analyze its
effect on viral replication, hence viral production. In this work, we show that such dimer inter-
face peptides can impair in a dose dependent manner in vitro dimer formation of a peptide
containing the two α-helices that make up the 3A dimer interface. This effect was higher with
peptide α12, spanning the two hydrophobic α-helices. Dimer inhibition was also observed in
cells transiently expressing the complete 3A protein. To this end, the interfering peptides α1
and α12 were N-terminally fused to a heptaarginine (R7) sequence, a well-known CPP motif
that favors intracellular translocation [15, 17]. Thus, when fused to R7, interference peptides
(100 μM) were able to inhibit in situ dimerization of transiently expressed 3A, the higher inhi-
bitions being found with R7-fused peptides α1 and α12. The 3A protein dimerization
impairment exerted by the peptides correlated with significant reductions in the viral yield
recovered from peptide-treated FMDV infected cells. In this case, α2 was the only R7-fused
peptide producing significant reductions at concentrations lower than 100 μM. The discrepan-
cies observed in the inhibitions exerted by α2 in in situ dimer formation (Fig 3B) and viral
yield (Fig 4A) could reflect differences in the amount, time-course and interaction with cell
components between transiently expressed 3A and that synthesized in the context of virus
infection in a manner accomplished with the other virus proteins. The virus yield reduction
observed was specific for FMDV as no significant effect was observed in peptide-treated cells
infected with BEV.
Taken together, the above findings show the feasibility of inhibiting FMDV 3A dimerization
by means of peptides reproducing the dimer interface, and the effect of this inhibition on virus
multiplication, providing with a tool to understand the structure-function relationship of this
viral protein and pointing to 3A dimerization as a potential antiviral target.
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